Sign In
Buy RCUS
$28.42
-1.31 (-4.41%)
At Close: Jul 24, 2026
Arcus Biosciences Announces New Employment Inducement Grants
04:15pm, Wednesday, 24'th Mar 2021
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensa
Arcus Biosciences, Inc. (RCUS) Stock Jumps 9.5%: Will It Continue to Soar?
01:17pm, Friday, 12'th Mar 2021
Arcus Biosciences, Inc. (RCUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stren
Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights
04:10pm, Wednesday, 24'th Feb 2021
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results
Arcus Biosciences to Participate in Upcoming Investor Conferences
04:10pm, Thursday, 11'th Feb 2021
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management w
Gilead buys more Arcus Biosciences stock, at a price above the record close
08:13am, Monday, 01'st Feb 2021
Arcus Biosciences Inc. disclosed Monday that Gilead Sciences Inc. boosted its stake in the oncology-focused biopharmaceutical company, through the purchase of $220.35 million worth of stock. Arcus sha
Arcus Biosciences Announces New Employment Inducement Grants
04:10pm, Tuesday, 26'th Jan 2021
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensa
Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer
08:03am, Friday, 15'th Jan 2021
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data
Arcus Biosciences Announces New Employment Inducement Grants
04:10pm, Tuesday, 12'th Jan 2021
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensa
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that preliminary
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlm
Are Options Traders Betting on a Big Move in Arcus Biosciences (RCUS) Stock?
09:11am, Monday, 04'th Jan 2021
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269.HK), a g
Arcus Biosciences to Participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference
04:10pm, Wednesday, 18'th Nov 2020
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management w
Arcus Biosciences Announces New Employment Inducement Grants
05:30pm, Tuesday, 10'th Nov 2020
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensa
